Abstract：
UNASSIGNED: Biological medications have significantly improved the prognosis of psoriasis patients. All biological drugs (except infliximab) for psoriasis require subcutaneous (SC) administration. Adverse events of biologic drug treatment include injection site reactions. ISRs are a local phenomenon characterized by swelling, erythema, pruritus, and pain around the injection site.
UNASSIGNED: We conducted a review to analyze the differences between the ISRs of various biologics approved for psoriasis. Specifically, the review focused on anti-TNF-α, anti-IL12/23, anti-IL-17, and anti-IL-23 drugs.
UNASSIGNED: Etanercept and adalimumab have reported ISR rates of 37% and 20%, respectively, with erythema, pruritus, pain, and irritation being the most common. Citrate free (CF) solution and thinner needles have reduced ISR associated with adalimumab. Ustekinumab showed a low risk of ISR. Regarding secukinumab and ixekizumab, pain was found to be the most common ISR. The introduction of CF ixekizumab formulation has shown promise in reducing ISRs associated with ixekizumab. The risk of ISR appears insignificant with bimekizumab, brodalumab, and anti-IL23 drugs, with ISR rates ranging from less than 1% to 7.1%. The choice of biologic agent should consider ISR risk. Education on injection techniques and the use of single-dose autoinjectors/pens can mitigate ISR risk.
UNASSIGNED: We conducted a review to analyze the differences between the ISRs of various biologics approved for psoriasis. Specifically, the review focused on anti-TNF-α, anti-IL12/23, anti-IL-17, and anti-IL-23 drugs.
UNASSIGNED: Etanercept and adalimumab have reported ISR rates of 37% and 20%, respectively, with erythema, pruritus, pain, and irritation being the most common. Citrate free (CF) solution and thinner needles have reduced ISR associated with adalimumab. Ustekinumab showed a low risk of ISR. Regarding secukinumab and ixekizumab, pain was found to be the most common ISR. The introduction of CF ixekizumab formulation has shown promise in reducing ISRs associated with ixekizumab. The risk of ISR appears insignificant with bimekizumab, brodalumab, and anti-IL23 drugs, with ISR rates ranging from less than 1% to 7.1%. The choice of biologic agent should consider ISR risk. Education on injection techniques and the use of single-dose autoinjectors/pens can mitigate ISR risk.
摘要：
■生物药物显著改善银屑病患者的预后。用于牛皮癣的所有生物药物（英夫利昔单抗除外）都需要皮下（SC）给药。生物药物治疗的不良事件包括注射部位反应。ISR是一种以肿胀为特征的局部现象，红斑,瘙痒,注射部位疼痛.
■我们进行了一项综述，以分析批准用于牛皮癣的各种生物制剂的ISR之间的差异。具体来说,这篇综述集中在抗TNF-α，抗IL12/23，抗IL-17和抗IL-23药物。
■依那西普和阿达木单抗报告的ISR率为37％和20％，分别,红斑,瘙痒,疼痛,和刺激是最常见的。无柠檬酸盐（CF）溶液和较薄的针头降低了与阿达木单抗相关的ISR。Ustekinumab显示ISR的低风险。关于苏金单抗和ixekizumab，发现疼痛是最常见的ISR。CFixekizumab制剂的引入已显示出减少与ixekizumab相关的ISR的希望。使用bimekizumab时，ISR的风险似乎微不足道，Brodalumab,和抗IL23药物，ISR率从不到1%到7.1%不等。生物制剂的选择应考虑ISR风险。注射技术教育和使用单剂量自动注射器/笔可以减轻ISR风险。
■我们进行了一项综述，以分析批准用于牛皮癣的各种生物制剂的ISR之间的差异。具体来说,这篇综述集中在抗TNF-α，抗IL12/23，抗IL-17和抗IL-23药物。
■依那西普和阿达木单抗报告的ISR率为37％和20％，分别,红斑,瘙痒,疼痛,和刺激是最常见的。无柠檬酸盐（CF）溶液和较薄的针头降低了与阿达木单抗相关的ISR。Ustekinumab显示ISR的低风险。关于苏金单抗和ixekizumab，发现疼痛是最常见的ISR。CFixekizumab制剂的引入已显示出减少与ixekizumab相关的ISR的希望。使用bimekizumab时，ISR的风险似乎微不足道，Brodalumab,和抗IL23药物，ISR率从不到1%到7.1%不等。生物制剂的选择应考虑ISR风险。注射技术教育和使用单剂量自动注射器/笔可以减轻ISR风险。
